OTC Markets OTCPK - Delayed Quote USD

Hikma Pharmaceuticals PLC (HKMPY)

Compare
48.64 0.00 (0.00%)
At close: September 24 at 4:00 PM EDT
Loading Chart for HKMPY
DELL
  • Previous Close 0.00
  • Open 50.50
  • Bid 48.65 x 40000
  • Ask 52.67 x 40000
  • Day's Range 50.50 - 50.50
  • 52 Week Range 42.23 - 55.56
  • Volume 100
  • Avg. Volume 130
  • Market Cap (intraday) 5.529B
  • Beta (5Y Monthly) 0.41
  • PE Ratio (TTM) 28.61
  • EPS (TTM) 1.70
  • Earnings Date Aug 8, 2024
  • Forward Dividend & Yield 1.58 (3.25%)
  • Ex-Dividend Date Aug 19, 2024
  • 1y Target Est --

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.

www.hikma.com

9,100

Full Time Employees

December 31

Fiscal Year Ends

Recent News: HKMPY

View More

Performance Overview: HKMPY

Trailing total returns as of 9/25/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

HKMPY
10.49%
FTSE 100
7.39%

1-Year Return

HKMPY
4.43%
FTSE 100
8.08%

3-Year Return

HKMPY
21.58%
FTSE 100
17.77%

5-Year Return

HKMPY
12.38%
FTSE 100
13.90%

Compare To: HKMPY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: HKMPY

View More

Valuation Measures

Annual
As of 9/24/2024
  • Market Cap

    5.51B

  • Enterprise Value

    6.47B

  • Trailing P/E

    28.61

  • Forward P/E

    11.96

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.88

  • Price/Book (mrq)

    2.46

  • Enterprise Value/Revenue

    2.25

  • Enterprise Value/EBITDA

    11.73

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.45%

  • Return on Assets (ttm)

    9.40%

  • Return on Equity (ttm)

    12.88%

  • Revenue (ttm)

    3.02B

  • Net Income Avi to Common (ttm)

    285M

  • Diluted EPS (ttm)

    1.70

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    260M

  • Total Debt/Equity (mrq)

    55.48%

  • Levered Free Cash Flow (ttm)

    410.38M

Company Insights: HKMPY

People Also Watch